After months of planning, consultation and preparation, today we launched our new research structure.
Thursday 26 September is the inaugural Childhood Brain Cancer Awareness Day. This year, we shine a light on Diffuse Intrinsic Pontine Glioma (DIPG), the most devastating of all childhood cancers.
Our researchers have discovered that a gene called JMJD6 plays an important role in the most aggressive form of neuroblastoma. What’s more, they’ve developed a targeted treatment against it.
Looking for a PhD scheme that combines outstanding supervision, an exceptional research environment and an individualised professional development plan? The UNSW Scientia PhD Scholarship Scheme 2020 is now open. Only those determined to make a difference in the world need apply.
Our researchers have found a way to dramatically slow neuroblastoma growth, using a combination of drugs that starves cells of essential nutrients called polyamines.
Groundbreaking research from our Leukaemia Biology Program has revealed how acute lymphoblastic leukaemia can become resistant to a class of anti-cancer drugs called glucocorticoids.
Curing childhood cancer requires global effort. In this new blog series, you’ll meet some of the many national and international partners who are working with us to make it happen. We’ll start with Cancer Therapeutics CRC.
A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
This week we’re looking at immunotherapy. Harnessing the power of the immune system against cancer is yielding some amazing results. So what are the promises and challenges of immunotherapy?
This week we’re exploring cancer genomics. What is it, why is it important, and how can we use it to improve cancer treatment?